The DOI matches its Crossref record; 245 of the 247 references it cites were found in a registry or an index.
Neuropathological Alterations in Alzheimer Disease
Open accessAbstract
The neuropathological hallmarks of Alzheimer disease (AD) include "positive" lesions such as amyloid plaques and cerebral amyloid angiopathy, neurofibrillary tangles, and glial responses, and "negative" lesions such as neuronal and synaptic loss. Despite their inherently cross-sectional nature, postmortem studies have enabled the staging of the progression of both amyloid and tangle pathologies, and, consequently, the development of diagnostic criteria that are now used worldwide. In addition, clinicopathological correlation studies have been crucial to generate hypotheses about the pathophysiology of the disease, by establishing that there is a continuum between "normal" aging and AD dementia, and that the amyloid plaque build-up occurs primarily before the onset of cognitive deficits, while neurofibrillary tangles, neuron loss, and particularly synaptic loss, parallel the progression of cognitive decline. Importantly, these cross-sectional neuropathological data have been largely validated by longitudinal in vivo studies using modern imaging biomarkers such as amyloid PET and volumetric MRI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, Lewy pathology in AD is most frequent in olfactory bulb and the amygdala [23, 123].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The direct connection between Aβ and MAPT pathology is poorly understood, as shown by the weak correlation between the distribution of Aβ pathology and the distribution of MAPT pathology in humans (Serrano-Pozo et al., 2011; Perez-Nievas et al., 2013; Scheltens et al., 2021).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Serrano-Pozo et al., 2011
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Some of the dystrophic neurites associated with neuritic plaques contain tau filaments, which can have a paired helical filament morphology with electron microscopy [23].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally eosinophilic Hirano bodies, granulovacuolar degeneration (GVD) and cerebral amyloid angiopathy (CAA) are also common [18, 23].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“Dense cored NPs are also accompanied by synaptic loss, activated microglia and reactive astrocytes [23, 29, 36].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“Amyloid deposits in CAA are enriched in Aβ40 (while parenchymal deposits are enriched in Aβ42 species) and can affect small arteries, arterioles and even capillaries of the gray matter of the cerebral cortices and in leptomeningeal vessels [18, 23].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly the parietal and occipital cortices are more vulnerable than the frontal and temporal lobes, and leptomeningeal arteries are more vulnerable than parenchymal vessels [23].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“Alzheimer’s pathology can be found in cognitively normal patients at the time of autopsy, and this preclinical phase can also be observed in patients with mild cognitive impairment that do not meet the criteria for clinical AD [4, 23].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“Accumulation of amyloid-beta (Αβ) is a histological hallmark of the AD brain1.”
From Amyloid-β induces lipid droplet-mediated microglial dysfunction via the enzyme DGAT2 in Alzheimer’s disease (2025) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“AD is the leading cause of dementia characterized by key neuronal hallmarks: extracellular deposition of Aβ plaques, formation of intracellular neurofibrillary tangles, and neuronal loss (1, 2).”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Neurodegeneration is a pathological hallmark of AD 20 , which is exacerbated in a mouse model of tauopathy expressing APOE4 (refs. 12,21).”
From APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints (2023) · cites this paper as [20]
In the citing paper
“The amyloid hypothesis of AD posits that excessive accumulation of amyloid-β peptide leads to neurofibrillary tangles composed of aggregated hyperphosphorylated tau84.”
From The use of brain organoids to investigate neural development and disease (2017) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedTsigelny, I. F., Crews, L., Desplats, P., Shaked, G. M., Sharikov, Y., Mizuno, H., Spencer, B., Rockenstein, E., Trejo, M., Platoshyn, O., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003135 · Cited by 281
Self-citationRetractedNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 9×
“The NFTs are argyrophilic and can be shown by silver impregnation methods such as the Gallyas technique (Braak and Braak 1991).”
BackgroundMethodInfluentialMild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Current concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Flagged first, then by citations
2 of the 247 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- [200]200. Terry R, Hansen L, Masliah E. 1994. Structural basis of the cognitive alterations in Alzheimer disease. In Alzheimer disease (ed. R. Terry, R. Katzman), pp. 179 -196.
Cited by
Sorted by citations
Items 101–200 of 1,029
Dendritic spines: Revisiting the physiological role
Chidambaram, S. B., Rathipriya, A. G., Bolla, S. R., Bhat, A., Ray, B., Mahalakshmi, A. M., Manivasagam, T., Thenmozhi, A. J., Essa, M. M., Guillemin, G. J., et al. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.01.005 · Cited by 266
The Pharmacological Action of Kaempferol in Central Nervous System Diseases: A Review
dos Santos, J. S., Cirino, J. P. G., Carvalho, P. D. O., & Ortega, M. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.565700 · Cited by 262
Aging Microglia—Phenotypes, Functions and Implications for Age-Related Neurodegenerative Diseases
Spittau, B. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00194 · Cited by 271
The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer's disease
Cheng-Hathaway, P. J., Reed-Geaghan, E. G., Jay, T. R., Casali, B. T., Bemiller, S. M., Puntambekar, S. S., von Saucken, V. E., Williams, R. Y., Karlo, J. C., Moutinho, M., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0262-8 · Cited by 252
Impact of TREM2R47H variant on tau pathology–induced gliosis and neurodegeneration
Gratuze, M., Leyns, C. E. G., Sauerbeck, A. D., St-Pierre, M.-K., Xiong, M., Kim, N., Serrano, J. R., Tremblay, M.-È., Kummer, T. T., Colonna, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138179 · Cited by 252
Neuroprotective Effects of Coffee Bioactive Compounds: A Review
Socała, K., Szopa, A., Serefko, A., Poleszak, E., & Właź, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010107 · Cited by 271
Saleem, S., & Kannan, R. R. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0109-7 · Cited by 241
The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases
Wu, M., Zhang, M., Yin, X., Chen, K., Hu, Z., Zhou, Q., Cao, X., Chen, Z., & Liu, D. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00270-1 · Cited by 241
TDP-43 depletion in microglia promotes amyloid clearance but also induces synapse loss
Paolicelli, R. C., Jawaid, A., Henstridge, C. M., Valeri, A., Merlini, M., Robinson, J. L., Lee, E. B., Rose, J., Appel, S., Lee, V. M.-Y., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.05.037 · Cited by 239
Protein misfolding and aggregation in Alzheimer’s disease and type 2 diabetes mellitus
Ashraf, G., Greig, N., Khan, T., Hassan, I., Tabrez, S., Shakil, S., Sheikh, I., Zaidi, S., Akram, M., Jabir, N., et al. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140917095514 · Cited by 236
Neuronal cell death mechanisms in Alzheimer’s disease: An insight
Goel, P., Chakrabarti, S., Goel, K., Bhutani, K., Chopra, T., & Bali, S. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.937133 · Cited by 248
Different Brain Regions are Infected with Fungi in Alzheimer’s Disease
Pisa, D., Alonso, R., Rábano, A., Rodal, I., & Carrasco, L. (2015) · Scientific Reports · doi:10.1038/srep15015 · Cited by 248
Knight, E. M., Martins, I. V. A., Gümüsgöz, S., Allan, S. M., & Lawrence, C. B. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.02.010 · Cited by 232
“In humans, the severity of AD-related neuropathology especially Ab plaque burden, does not always correlate with, or is predictive of, cognitive deficits, and memory impairments can occur in mouse AD models in advance of overt Ab plaque (and tangle) pathology (Billings et al., 2005; Oddo et al., 2003b; Serrano-Pozo et…”
Ravanfar, P., Loi, S. M., Syeda, W. T., Rheenen, T. E. V., Bush, A. I., Desmond, P. M., Cropley, V., Lane, D. J. R., Opazo, C., Moffat, B. A., et al. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.618435 · Cited by 231
Tang, Z., Chuang, K. V., DeCarli, C. S., Jin, L., Beckett, L. A., Keiser, M. J., & Dugger, B. N. (2019) · Nature Communications · doi:10.1038/s41467-019-10212-1 · Cited by 234
The Dynamic Duo: Combining noninvasive brain stimulation with cognitive interventions
Sathappan, A. V., Luber, B. M., & Lisanby, S. H. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.10.006 · Cited by 234
Serrano-Pozo, A., Muzikansky, A., Gómez-Isla, T., Growdon, J. H., Betensky, R. A., Frosch, M. P., & Hyman, B. T. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182933788 · Cited by 226
Self-citationWhat Happens with the Circuit in Alzheimer's Disease in Mice and Humans?
Zott, B., Busche, M. A., Sperling, R. A., & Konnerth, A. (2018) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-080317-061725 · Cited by 221
Azman, K. F., & Zakaria, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126827 · Cited by 244
Oxidant/Antioxidant Imbalance in Alzheimer’s Disease: Therapeutic and Diagnostic Prospects
Wojsiat, J., Zoltowska, K. M., Laskowska-Kaszub, K., & Wojda, U. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6435861 · Cited by 221
Ketogenic Diet in Neuromuscular and Neurodegenerative Diseases
Paoli, A., Bianco, A., Damiani, E., & Bosco, G. (2014) · BioMed Research International · doi:10.1155/2014/474296 · Cited by 221
Li, N., Kaur, P., Bunnag, N., Suresh, J., Sung, I. C. H., Tan, Q. H., Gruber, J., & Tolwinski, N. S. (2019) · Cells · doi:10.3390/cells8080826 · Cited by 228
Song, Q., Huang, M., Yao, L., Wang, X., Gu, X., Chen, J., Chen, J., Huang, J., Hu, Q., Kang, T., et al. (2014) · ACS Nano · doi:10.1021/nn4058215 · Cited by 219
Pinton, S., Sampaio, T. B., Savall, A. S. P., & Gutierrez, M. Z. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.205084 · Cited by 220
TREM2, microglia, and Alzheimer’s disease.
Qin, Q., Teng, Z., Liu, C., Li, Q., Yin, Y., & Tang, Y. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111438 · Cited by 219
Diet, nutrition and the ageing brain: current evidence and new directions
Moore, K., Hughes, C., Ward, M., Hoey, L., & McNulty, H. (2018) · Proceedings of The Nutrition Society · doi:10.1017/s0029665117004177 · Cited by 227
Review of Current Strategies for Delivering Alzheimer’s Disease Drugs across the Blood-Brain Barrier
Wong, K. H., Riaz, M. K., Xie, Y., Zhang, X., Liu, Q., Chen, H., Bian, Z., Chen, X., Lü, A., & Yang, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020381 · Cited by 228
Activated microglia mitigate Aβ-associated tau seeding and spreading
Gratuze, M., Chen, Y., Parhizkar, S., Jain, N., Strickland, M. R., Serrano, J. R., Colonna, M., Ulrich, J. D., & Holtzman, D. M. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20210542 · Cited by 215
Behavioral assays with mouse models of Alzheimer's disease: Practical considerations and guidelines
Puzzo, D., Lee, L. S., Palmeri, A., Calabrese, G., & Arancio, O. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.011 · Cited by 226
Lu, Y., Dong, Y., Tucker, D., Wang, R., Ahmed, M. E., Brann, D. W., & Zhang, Q. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160869 · Cited by 222
Blood–Brain Barrier Breakdown in Alzheimer’s Disease: Mechanisms and Targeted Strategies
Alkhalifa, A. E., Al-Ghraiybah, N. F., Odum, J., Shunnarah, J. G., Austin, N., & Kaddoumi, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216288 · Cited by 212
Impact of Cytokines and Chemokines on Alzheimer’s Disease Neuropathological Hallmarks
Domingues, C., da Cruz e Silva, O. A. B., & Henriques, A. G. (2017) · Current Alzheimer Research · doi:10.2174/1567205014666170317113606 · Cited by 203
Molecular Mechanism of Arsenic-Induced Neurotoxicity including Neuronal Dysfunctions
Thakur, M., Rachamalla, M., Niyogi, S., Datusalia, A. K., & Flora, S. J. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810077 · Cited by 222
18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy
Passamonti, L., Rodríguez, P. V., Hong, Y. T., Allinson, K. S. J., Williamson, D., Borchert, R. J., Sami, S. A. K., Cope, T., Bevan-Jones, W. R., Jones, P. S., et al. (2016) · Brain · doi:10.1093/brain/aww340 · Cited by 210
Brkic, M., Balusu, S., Libert, C., & Vandenbroucke, R. E. (2015) · Mediators of Inflammation · doi:10.1155/2015/620581 · Cited by 205
A role for tau at the synapse in Alzheimer’s disease pathogenesis
Pooler, A. M., Noble, W., & Hanger, D. P. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.09.018 · Cited by 203
Yamazaki, Y., Shinohara, M., Shinohara, M., Yamazaki, A., Murray, M. E., Liesinger, A. M., Heckman, M. G., Lesser, E. R., Parisi, J. E., Petersen, R. C., et al. (2019) · Brain · doi:10.1093/brain/awz011 · Cited by 202
Role of Environmental Toxicants on Neurodegenerative Disorders
Nabi, M., & Tabassum, N. (2022) · Frontiers in Toxicology · doi:10.3389/ftox.2022.837579 · Cited by 217
Colom-Cadena, M., Davies, C., Sirisi, S., Lee, J.-E., Simzer, E. M., Tzioras, M., Querol-Vilaseca, M., Sánchez-Aced, É., Chang, Y. Y., Holt, K., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.04.020 · Cited by 224
APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints
Yin, Z., Rosenzweig, N., Kleemann, K. L., Zhang, X., Brandão, W., Margeta, M. A., Schroeder, C., Sivanathan, K. N., Silveira, S., Gauthier, C., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01627-6 · Cited by 202
Glial Cell-Mediated Neuroinflammation in Alzheimer’s Disease
Al-Ghraiybah, N. F., Wang, J., Alkhalifa, A. E., Roberts, A. B., Raj, R., Yang, E., & Kaddoumi, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810572 · Cited by 212
Amyloid-β and Tau at the Crossroads of Alzheimer’s Disease
Gallardo, G., & Holtzman, D. M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9358-8_16 · Cited by 212
Ramakrishna, K., Nalla, L. V., Dumala, N., Venkateswarlu, K., Viswanadh, M. K., Nalluri, B. N., Chakravarthy, G., Duguluri, S., Singh, P., Nand, S., et al. (2023) · Diseases · doi:10.3390/diseases11030089 · Cited by 206
Stutzbach, L. D., Xie, S. X., Naj, A. C., Albin, R., Gilman, S., PSP Genetics Study Group, Lee, V. M. Y., Trojanowski, J. Q., Devlin, B., & Schellenberg, G. D. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-31 · Cited by 197
SIRT1 and SIRT2 Activity Control in Neurodegenerative Diseases
Manjula, R., Anuja, K., & Alcain, F. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.585821 · Cited by 197
Early-Onset Alzheimer’s Disease: What Is Missing in Research?
Ayodele, T., Rogaeva, E. A., Kurup, J. T., Beecham, G. W., & Reitz, C. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01090-y · Cited by 210
Emrani, S., Arain, H. A., DeMarshall, C. A., & Nuriel, T. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00712-4 · Cited by 207
Ruan, S., Zhou, Y., Jiang, X., & Gao, H. (2021) · Advanced Science · doi:10.1002/advs.202004025 · Cited by 200
Neurogenetic contributions to amyloid beta and tau spreading in the human cortex
Sepulcre, J., Grothe, M. J., Uquillas, F. D., Ortiz-Terán, L., Diez, I. P., Yang, H., Jacobs, H. I. L., Hanseeuw, B. J., Li, Q., Fakhri, G. E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0206-4 · Cited by 195
Vasconcelos, B., Stancu, I.-C., Buist, A., Bird, M., Wang, P., Vanoosthuyse, A., Van Kolen, K., Verheyen, A., Kienlen-Campard, P., Octave, J.-N., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1525-x · Cited by 192
The Therapeutic Potential of Rosemary (Rosmarinus officinalis) Diterpenes for Alzheimer’s Disease
Habtemariam, S. (2016) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2016/2680409 · Cited by 195
Sex Hormones and Cognition: Neuroendocrine Influences on Memory and Learning
Hamson, D. K., Roes, M., & Galea, L. A. M. (2016) · Comprehensive physiology · doi:10.1002/cphy.c150031 · Cited by 216
Bourdenx, M., Koulakiotis, N. S., Sanoudou, D., Bézard, E., Dehay, B., & Tsarbopoulos, A. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.003 · Cited by 202
Gascon, E., Lynch, K., Ruan, H., Almeida, S., Verheyden, J. M., Seeley, W. W., Dickson, D. W., Petrucelli, L., Sun, D., Jiao, J., et al. (2014) · Nature Medicine · doi:10.1038/nm.3717 · Cited by 183
Hansen, H. H., Fabricius, K., Barkholt, P., Niehoff, M. L., Morley, J. E., Jelsing, J., Pyke, C., Knudsen, L. B., Farr, S. A., & Vrang, N. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-143090 · Cited by 193
Mitochondrial Dysfunction in Alzheimers Disease: Opportunities forDrug Development
Bhatia, S., Rawal, R., Sharma, P., Singh, T., Singh, M., & Singh, V. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210517114016 · Cited by 209
Gąsiorowska, A., Wydrych, M., Drapich, P., Zadrożny, M., Steczkowska, M., Niewiadomski, W., & Niewiadomska, G. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.654931 · Cited by 199
Jabir, N. R., Khan, F. R., & Tabrez, S. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12971 · Cited by 187
Altered arginine metabolism in Alzheimer's disease brains
Liu, P., Fleete, M. S., Yu, J., Collie, N. D., Curtis, M. A., Waldvogel, H. J., Faull, R. L. M., Abraham, W. C., & Zhang, H. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.013 · Cited by 187
Satoh, J., Kino, Y., & Niida, S. (2015) · Biomarker Insights · doi:10.4137/bmi.s25132 · Cited by 181
Effects of imperatorin on scopolamine-induced cognitive impairment and oxidative stress in mice
Budzyńska, B., Boguszewska‐Czubara, A., Kruk-Słomka, M., Skalicka‐Woźniak, K., Michalak, A., Musik, I., & Biała, G. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3728-6 · Cited by 184
Docosahexaenoic acid: one molecule diverse functions
Hashimoto, M., Hossain, S., Mamun, A. A., Matsuzaki, K., & Arai, H. (2016) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2016.1207153 · Cited by 191
Kim, K. H., Lee, D., Lee, H. L., Kim, C.-E., Jung, K., & Kang, K. S. (2017) · Journal of Ginseng Research · doi:10.1016/j.jgr.2017.03.011 · Cited by 188
Dupont, A.-C., Largeau, B., Santiago Ribeiro, M., Guilloteau, D., Tronel, C., & Arlicot, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040785 · Cited by 182
“Unlike NFTs, amyloid plaques deposition showed a lesser stereotypical spatiotemporal pattern of progression; they accumulate mainly in the isocortex, and the amyloid burden does not correlate with the severity or the duration of dementia [117,118].”
BackgroundAxonal Degeneration during Aging and Its Functional Role in Neurodegenerative Disorders
Salvadores, N., Sanhueza, M., Manque, P., & Court, F. A. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00451 · Cited by 182
Neurodegeneration and microtubule dynamics: death by a thousand cuts
Dubey, J., Ratnakaran, N., & Koushika, S. P. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00343 · Cited by 193
Colocalization of cerebral iron with Amyloid beta in Mild Cognitive Impairment
Bergen, J. M. G. V., Li, X., Hua, J., Schreiner, S. J., Steininger, S. C., Quevenco, F. C., Wyss, M. T., Gietl, A. F., Treyer, V., Leh, S. E., et al. (2016) · Scientific Reports · doi:10.1038/srep35514 · Cited by 186
Epigenetics of Alzheimer’s Disease
Perković, M. N., Paska, A. V., Konjevod, M., Kouter, K., Štrac, D. Š., Erjavec, G. N., & Pivac, N. (2021) · Biomolecules · doi:10.3390/biom11020195 · Cited by 192
The State of The Art on Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s Disease
Vecchio, I., Sorrentino, L., Paoletti, A., Marra, R., & Arbitrio, M. (2021) · Journal of Central Nervous System Disease · doi:10.1177/11795735211029113 · Cited by 189
Mechanisms of Pathogenic Tau and Aβ Protein Spreading in Alzheimer’s Disease
d’Errico, P., & Meyer‐Luehmann, M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00265 · Cited by 191
Developing novel blood‐based biomarkers for Alzheimer's disease
Snyder, H. M., Carrillo, M. C., Grodstein, F., Henriksen, K., Jeromin, A., Lovestone, S., Mielke, M. M., O'Bryant, S., Sarasa, M., Sj⊘gren, M., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.10.007 · Cited by 177
Chen, X., & Mobley, W. C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00446 · Cited by 179
Ferrer, I. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.03.005 · Cited by 174
In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain
Sepulcre, J., Schultz, A. P., Sabuncu, M. R., Gómez‐Isla, T., Chhatwal, J. P., Becker, A., Sperling, R. A., & Johnson, K. A. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0639-16.2016 · Cited by 182
Late-onset vs nonmendelian early-onset Alzheimer disease
Reitz, C., Rogaeva, E. A., & Beecham, G. W. (2020) · Neurology Genetics · doi:10.1212/nxg.0000000000000512 · Cited by 184
A CNN based framework for classification of Alzheimer’s disease
AbdulAzeem, Y., Bahgat, W. M., & Badawy, M. (2021) · Neural Computing and Applications · doi:10.1007/s00521-021-05799-w · Cited by 183
Barone, E., Domenico, F. D., Marzia Perluigi, A., & Butterfield, D. A. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.09.006 · Cited by 182
Deciphering Alzheimer DiseasePreprint
Selkoe, D. J., Mandelkow�, E., & Holtzman, D. M. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011460 · Cited by 175
Epigenetic Alterations in Alzheimer’s Disease
Sanchez-Mut, J. V., & Gräff, J. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00347 · Cited by 175
Nanotechnology-based drug delivery for central nervous system disorders
Nguyen, T. T., Nguyen, T. T. D., Vo, T. K., An, T. N. M., Nguyen, M. K., Toi, V. V., & Vo, G. V. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112117 · Cited by 182
Nec‐1 alleviates cognitive impairment with reduction of Aβ and tau abnormalities in APP/PS1 mice
Yang, S., Lee, D. K., Shin, J., Lee, S., Baek, S., Kim, J., Jung, H., Hah, J., & Kim, Y. S. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606566 · Cited by 172
The Second Activating Glucokinase Mutation (A456V)
Christesen, H. T., Jacobsen, B. B., Odili, S., Buettger, C. W., Cuesta-Muñoz, A. L., Hansen, T. F., Brusgaard, K., Massa, O., Magnuson, M. A., Shiota, C., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1240 · Cited by 172
The Role of the Tripartite Glutamatergic Synapse in the Pathophysiology of Alzheimer’s Disease
Rudy, C. C., Hunsberger, H. C., Weitzner, D. S., & Reed, M. N. (2015) · Aging and Disease · doi:10.14336/ad.2014.0423 · Cited by 187
Integrins in synapse regulation
Park, Y. K., & Goda, Y. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.138 · Cited by 167
Tapia‐Rojas, C., Aránguiz, F. C., Varela‐Nallar, L., & Inestrosa, N. C. (2015) · Brain Pathology · doi:10.1111/bpa.12255 · Cited by 176
Tau Oligomers: The Toxic Player at Synapses in Alzheimer’s Disease
Guerrero-Muñoz, M. J., Gerson, J., & Castillo-Carranza, D. L. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00464 · Cited by 168
Sleep in Alzheimer's Disease–Beyond Amyloid
Holth, J. K., Patel, T. K., & Holtzman, D. M. (2016) · Neurobiology of Sleep and Circadian Rhythms · doi:10.1016/j.nbscr.2016.08.002 · Cited by 180
Mammana, S., Fagone, P., Cavalli, E., Basile, M. S., Petralia, M. C., Nicoletti, F., Bramanti, P., & Mazzon, E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030831 · Cited by 171
Bouhrara, M., Reiter, D. A., Bergeron, C. M., Zukley, L. M., Ferrucci, L., Resnick, S. M., & Spencer, R. G. S. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.03.007 · Cited by 168
Protein-Capped Metal Nanoparticles Inhibit Tau Aggregation in Alzheimer’s Disease
Sonawane, S. K., Ahmad, A., & Chinnathambi, S. (2019) · ACS Omega · doi:10.1021/acsomega.9b01411 · Cited by 170
Signaling pathway cross talk in Alzheimer’s disease
Godoy, J. A., Ríos, J. A., Zolezzi, J. M., Braidy, N., & Inestrosa, N. C. (2014) · Cell Communication and Signaling · doi:10.1186/1478-811x-12-23 · Cited by 165
Rutjes, A. W., Denton, D. A., Di Nisio, M., Chong, L.-Y., Abraham, R. P., Al-Assaf, A. S., Anderson, J. L., Malik, M. A., Vernooij, R. W., Martínez, G., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011906.pub2 · Cited by 164
Fabelo, N., Martín, M. V., Marín, R., Moreno, D., Ferrer, I., & Díaz, M. L. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.02.005 · Cited by 169
Yamazaki, Y., Painter, M. M., Bu, G., & Kanekiyo, T. (2016) · CNS Drugs · doi:10.1007/s40263-016-0361-4 · Cited by 173
Low-level laser therapy for beta amyloid toxicity in rat hippocampus
Lu, Y., Wang, R., Dong, Y., Tucker, D., Zhao, N., Ahmed, M. E., Zhu, L., Liu, T. C., Cohen, R. M., & Zhang, Q. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.10.003 · Cited by 165
Sex differences in the prevalence and incidence of mild cognitive impairment: A meta-analysis
Au, B., Dale-McGrath, S., & Tierney, M. C. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.09.005 · Cited by 172
Moreno–Grau, S., de Rojas, I., Hernández, I., Quintela, I., Montrreal, L., Alegret, M., Hernández‐Olasagarre, B., Madrid, L., González‐Pérez, A., Maroñas, O., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.06.4950 · Cited by 161
Limorenko, G., & Lashuel, H. A. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00127b · Cited by 168
Kandpal, M., Indari, O., Baral, B., Jakhmola, S., Tiwari, D., Bhandari, V., Pandey, R. K., Bala, K., Sonawane, A., & Jha, H. C. (2022) · Metabolites · doi:10.3390/metabo12111064 · Cited by 177
Reduced levels of protein recoding by A-to-I RNA editing in Alzheimer's disease
Khermesh, K., D'Erchia, A. M., Barak, M., Annese, A., Wachtel, C., Levanon, E. Y., Picardi, E., & Eisenberg, E. (2016) · RNA · doi:10.1261/rna.054627.115 · Cited by 160
Metadata
- Authors
- Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T.
- Affiliations
- Harvard University (US)
- University of California San Diego (US)
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2011-09-01
- Volume
- 1
- Issue
- 1
- Pages
- a006189-a006189
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3234452
- OpenAlex
- W2096963202
- Semantic Scholar
- 875ea5aa27548adac085b276cf2ba404af4ae139
- Cited by
- 3,345
- References
- 247
- Citations by year
- 2026: 150 · 2025: 269 · 2024: 316 · 2023: 343 · 2022: 348 · 2021: 379 · 2020: 318 · 2019: 261 · 2018: 263 · 2017: 214 · 2016: 168 · 2015: 137 · 2014: 101 · 2013: 44 · 2012: 26
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (AG5131, AG08487, NS057096, AG10435, AG18840)
- National Institute on Aging (AG18840, AG-08487, P01AG010435, R37AG018440, P50AG005131, AG-5131, R01AG008487, P50 AG05134, P01AG022074, AG22074, P50AG005134, U19AG010483, AG10435)
- National Institute of Neurological Disorders and Stroke (P30NS057096, NS057096)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, neuropathology, amyloid plaques, cerebral amyloid angiopathy, neurofibrillary tangles, glial response, synaptic loss, neuronal loss, clinicopathological correlation, normal aging, cognitive decline, amyloid PET, volumetric MRI, imaging biomarkers
- MeSH terms
- Aging, Alzheimer Disease, Humans, Magnetic Resonance Imaging, Cerebral Amyloid Angiopathy, Neurofibrillary Tangles, Lewy Body Disease, Positron-Emission Tomography, Plaque, Amyloid, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
